LGVN — Longeveron Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1721484 ·
Last close
$2.11
Market Cap
$6.83M
52W High
$12.30
52W Low
$1.31
ADV30
92,243
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 115,000 | 71,000 | -7,197,000 | -6,135,000 | 12,015,000 | 7,245,000 | 7,305,000 |
| Jun 2026 | 287,000 | 182,000 | -6,171,000 | -6,073,000 | 15,487,000 | 10,077,000 | 5,085,000 |
| Mar 2026 | 398,000 | 264,000 | -4,775,000 | -4,736,000 | 21,210,000 | 15,758,000 | 5,183,000 |
| Dec 2025 | 365,000 | 257,000 | -5,399,000 | -5,444,000 | 10,261,000 | 4,661,000 | 4,586,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,374,000
Investing CF
$-305,000
Financing CF
$20,422,000
CapEx
$-305,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.10
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-143,120,000
Inventory
—
Receivables
$65,000
ST Investments
—
EBIT TTM
$-23,655,000
Pretax Income TTM
$-23,474,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,187,000
EBITDA
$-22,440,000
Free Cash Flow
$-11,603,375
Enterprise Value
$-27,051
Total Cash
$10,077,000
Total Debt
$581,000
Shares Out
3,234,935
Trailing EPS
$-7.95
Book Value
$2.48
ROE
-203.6%
ROA
-90.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,199,000 | -23,287,000 | -22,704,000 | 10,261,000 | 4,586,000 | 5,675,000 | -18,645,000 |
| Dec 2024 | 2,392,000 | -16,522,000 | -15,973,000 | 25,558,000 | 3,671,000 | 21,887,000 | -13,868,000 |
| Dec 2023 | 709,000 | -21,029,000 | -21,413,000 | 12,078,000 | 5,337,000 | 6,741,000 | -19,002,000 |
| Dec 2022 | 1,222,000 | -18,043,000 | -18,835,000 | 27,413,000 | 6,910,000 | 20,503,000 | -13,969,000 |
TTM Snapshot
Revenues TTM
$1,187,000
NetIncome TTM
$-23,474,000
OpCashFlow TTM
—
Assets (Latest)
$15,487,000
Forward EPS
$-1.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CVKD | Cadrenal Therapeutics, Inc. | $6.71M | $1.88 | — |
| MBRX | Moleculin Biotech, Inc. | $6.96M | $6.83 | — |
| IMRN | Immuron Ltd | $7.03M | $0.87 | — |
| XCUR | EXICURE, INC. | $7.07M | $1.08 | — |
| TPST | Tempest Therapeutics, Inc. | $6.54M | $0.33 | — |
News headlines (Yahoo Finance, 1h cache)
LGVN Has Multiple Options
2026-11-13 11:01 · Yahoo
Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
2026-11-12 21:54 · Yahoo
Longeveron Announces Engagement of Lucid Capital Markets
2026-10-28 13:15 · Yahoo
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
2026-10-26 13:15 · Yahoo
Longeveron to Participate in Three Longevity/Aging Investment Conferences
2026-09-30 20:05 · Yahoo
LGVN Posts Disappointing Trial Results
2026-09-17 11:14 · Yahoo
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
2026-09-16 21:27 · Yahoo
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 13:15 · Yahoo
Longeveron Announces 1-for-10 Reverse Stock Split
2026-08-24 20:05 · Yahoo
Longeveron (LGVN) Q2 2026 Earnings Call Transcript
2026-08-19 21:58 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.